2]- Albuterol ProAir RespiClick adrenergic agonists Formoterol Foradil Aerolizer Salmeterol Serevent Diskus Corticosteroids Budesonide Pulmicort Flexhaler Fluticasone propionate Flovent Diskus Fluticasone furoate Arnuity Ellipta Mometasone furoate Asmanex Twisthaler
Combinations Fluticasone Breo Ellipta furoate/vilanterol Fluticasone Advair Diskus propionate/salmeterol Device Comments type/drug class pMDIs (traditional) [Beta.
s Asmanex Twisthaler
for treating asthma in ages 4 to 11.
Asmanex Twisthaler (mometasone furoate inhalation powder, Schering-Plough Corp.
The Asmanex Twisthaler is not indicated for acute asthma episodes.
In one study, there was a significant improvement in mean forced expiratory volume in 1 second among 98 children treated with the Asmanex Twisthaler, compared with 99 using a placebo for 12 weeks.
The Food and Drug Administration approved Asmanex Twisthaler for once-daily maintenance treatment of asthma in children aged 4-11 years.
The Asmanex Twisthaler is not indicated for treatment of acute asthma episodes.
Some DPIs, such as AstraZeneca's Turbohaler design or the Asmanex Twisthaler
, contain a reservoir of powder containing the active ingredient.
The FDA approved Asmanex Twisthaler 220 mcg (mometasone furoate inhalation powder) for first-line maintenance treatment of asthma as preventive therapy in patients aged 12 years and older.
5 mg/day, on a weekly basis, after at least 1 week of Asmanex Twisthaler therapy.
ASMANEX TWISTHALER will not relieve sudden asthma symptoms and is not for children under the age of four.
ASMANEX TWISTHALER is available in two dose strengths, 110 mcg for children between 4 and 11 years old, and 220 mcg for patients 12 and older.